Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
A091990 Stock Overview
Celltrion Healthcare Co., Ltd. engages in the manufacture, processing, and sale of biosimilar and biological medicines to patients around the world.
Celltrion Healthcare Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩54,700.00 |
52 Week High | ₩123,333.33 |
52 Week Low | ₩53,800.00 |
Beta | 0.80 |
1 Month Change | -11.20% |
3 Month Change | -13.59% |
1 Year Change | -50.97% |
3 Year Change | -11.60% |
5 Year Change | n/a |
Change since IPO | 23.60% |
Recent News & Updates
Shareholder Returns
A091990 | KR Healthcare | KR Market | |
---|---|---|---|
7D | -8.8% | -4.6% | -1.8% |
1Y | -51.0% | -43.5% | -15.2% |
Return vs Industry: A091990 underperformed the KR Healthcare industry which returned -43.5% over the past year.
Return vs Market: A091990 underperformed the KR Market which returned -15.2% over the past year.
Price Volatility
A091990 volatility | |
---|---|
A091990 Average Weekly Movement | 6.2% |
Healthcare Industry Average Movement | 5.7% |
Market Average Movement | 5.6% |
10% most volatile stocks in KR Market | 10.4% |
10% least volatile stocks in KR Market | 3.2% |
Stable Share Price: A091990 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: A091990's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 131 | Hyoung Ki Kim | https://www.celltrionhealthcare.com |
Celltrion Healthcare Co., Ltd. engages in the manufacture, processing, and sale of biosimilar and biological medicines to patients around the world. Its products include Remsima, a monoclonal antibody biosimilar that is used for rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, adult Crohn's disease, Crohn's disease in children, psoriasis, and psoriatic arthritis; Truxima, which is used for lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis and microscopic polyangiitis, and rheumatoid arthritis; Herzuma that is used for metastatic breast cancer, early breast cancer, and metastatic gastric cancer; and Remsima SC, which is used for rheumatoid arthritis. The company was formerly known as Nexol, Inc. and changed its name to Celltrion Healthcare Co., Ltd.
Celltrion Healthcare Fundamentals Summary
A091990 fundamental statistics | |
---|---|
Market Cap | ₩8.52t |
Earnings (TTM) | ₩152.57b |
Revenue (TTM) | ₩1.80t |
55.8x
P/E Ratio4.7x
P/S RatioIs A091990 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A091990 income statement (TTM) | |
---|---|
Revenue | ₩1.80t |
Cost of Revenue | ₩1.37t |
Gross Profit | ₩430.50b |
Other Expenses | ₩277.93b |
Earnings | ₩152.57b |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
Earnings per share (EPS) | 979.54 |
Gross Margin | 23.86% |
Net Profit Margin | 8.45% |
Debt/Equity Ratio | 18.9% |
How did A091990 perform over the long term?
See historical performance and comparisonDividends
0.5%
Current Dividend Yield26%
Payout RatioValuation
Is Celltrion Healthcare undervalued compared to its fair value and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: A091990 (₩54700) is trading below our estimate of fair value (₩116277.98)
Significantly Below Fair Value: A091990 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: A091990 is poor value based on its PE Ratio (55.8x) compared to the Asian Healthcare industry average (18.1x).
PE vs Market: A091990 is poor value based on its PE Ratio (55.8x) compared to the KR market (14.1x).
Price to Earnings Growth Ratio
PEG Ratio: A091990 is poor value based on its PEG Ratio (1.9x)
Price to Book Ratio
PB vs Industry: A091990 is overvalued based on its PB Ratio (4x) compared to the KR Healthcare industry average (2.2x).
Future Growth
How is Celltrion Healthcare forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Future Growth Score
4/6Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
29.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: A091990's forecast earnings growth (29.4% per year) is above the savings rate (3.5%).
Earnings vs Market: A091990's earnings (29.4% per year) are forecast to grow faster than the KR market (14.8% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: A091990's revenue (13.2% per year) is forecast to grow faster than the KR market (9.6% per year).
High Growth Revenue: A091990's revenue (13.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: A091990's Return on Equity is forecast to be low in 3 years time (13.8%).
Past Performance
How has Celltrion Healthcare performed over the past 5 years?
Past Performance Score
2/6Past Performance Score 2/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
10.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: A091990 has high quality earnings.
Growing Profit Margin: A091990's current net profit margins (8.5%) are lower than last year (14.8%).
Past Earnings Growth Analysis
Earnings Trend: A091990's earnings have grown by 10% per year over the past 5 years.
Accelerating Growth: A091990's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: A091990 had negative earnings growth (-36.5%) over the past year, making it difficult to compare to the Healthcare industry average (34.1%).
Return on Equity
High ROE: A091990's Return on Equity (7.2%) is considered low.
Financial Health
How is Celltrion Healthcare's financial position?
Financial Health Score
5/6Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: A091990's short term assets (₩3,702.7B) exceed its short term liabilities (₩1,644.2B).
Long Term Liabilities: A091990's short term assets (₩3,702.7B) exceed its long term liabilities (₩164.7B).
Debt to Equity History and Analysis
Debt Level: A091990 has more cash than its total debt.
Reducing Debt: A091990's debt to equity ratio has reduced from 34.1% to 18.9% over the past 5 years.
Debt Coverage: A091990's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: A091990's interest payments on its debt are well covered by EBIT (20.7x coverage).
Balance Sheet
Dividend
What is Celltrion Healthcare current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
0.46%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: A091990's dividend (0.47%) isn’t notable compared to the bottom 25% of dividend payers in the KR market (0.85%).
High Dividend: A091990's dividend (0.47%) is low compared to the top 25% of dividend payers in the KR market (2.76%).
Stability and Growth of Payments
Stable Dividend: A091990 is not paying a notable dividend for the KR market, therefore no need to check if payments are stable.
Growing Dividend: A091990 is not paying a notable dividend for the KR market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: A091990 is not paying a notable dividend for the KR market.
Cash Payout to Shareholders
Cash Flow Coverage: A091990 is paying a dividend but the company has no free cash flows.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
CEO
Hyoung Ki Kim
no data
Tenure
Hyoung Ki Kim is CEO & Executive Director of Celltrion Healthcare Co., Ltd.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Celltrion Healthcare Co., Ltd.'s employee growth, exchange listings and data sources
Key Information
- Name: Celltrion Healthcare Co., Ltd.
- Ticker: A091990
- Exchange: KOSDAQ
- Founded: 1999
- Industry: Health Care Distributors
- Sector: Healthcare
- Implied Market Cap: ₩8.520t
- Shares outstanding: 155.75m
- Website: https://www.celltrionhealthcare.com
Number of Employees
Location
- Celltrion Healthcare Co., Ltd.
- Office Building: 19
- Academy-ro
- Incheon
- South Korea
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/05/14 00:00 |
End of Day Share Price | 2022/05/13 00:00 |
Earnings | 2021/12/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.